Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

 

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al. No. 2:22-cv-497 and Houlihan v. Kawas et al ., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.

 

The order set a final approval hearing for Thursday, July 18, 2024, at 10:30 am. As required by the order, the following materials have been posted to the Investor Relations section of Athira's website ( http://investors.athira.com/ ): the Zoom meeting information for the final approval hearing, the Stipulation of Settlement, a Summary Notice of Proposed Settlement of Stockholder Derivative Action, and a Notice of Proposed Settlement of Derivative Actions, Final Approval Hearing, and Right to Appear.

 

  About Athira Pharma, Inc.  
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, (formerly known as Twitter ) , and Instagram.

 

  Investor & Media Contact:  
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com  
206-769-9219

 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
Stallion Uranium Completes Shares for Debt

Stallion Uranium Completes Shares for Debt

 

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that, further to its news release dated May 22, 2025, the Company has settled its outstanding debt with Atha Energy Corp. ("Atha") on July 16, 2025 and issued 802,809 common shares of the Company to Atha at a deemed price of $0.135 per share.

 

  About Stallion Uranium Corp.  

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Athena Gold

Athena Gold Completes Till Survey At Laird Lake Project In Ontario's Red Lake Gold Camp

Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the successful completion of its comprehensive till survey at its Laird Lake gold project, located in Ontario's prolific Red Lake Gold District. The survey, completed ahead of schedule, marks a significant milestone in advancing the Company's exploration strategy on this highly prospective 4,158-hectare property, which spans over 10 km of the Balmer-Confederation Assemblage contact.

  

Keep reading...Show less
Stallion Uranium Announces the Completion of Coyote Project 3D Gravity Inversion

Stallion Uranium Announces the Completion of Coyote Project 3D Gravity Inversion

 

Stallion Uranium Corp. (the " Company " or " Stallion " ) (TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0) is pleased to report the results from the 3D inversion of ground gravity data over the Coyote Target, located within the Southwestern Athabasca Basin Joint Venture (" JV ") Project in partnership with Atha Energy Corp. ("Atha Energy") (TSX-V: SASK) .

 

"The inversion modelling at Coyote has delineated a laterally extensive and coherent gravity low, spatially coincident with a structurally complex corridor exhibiting attributes characteristic of fertile uranium-bearing systems within the Athabasca Basin," said Matthew Schwab, CEO of Stallion Uranium Corp. "The robustness of the geophysical anomaly, in conjunction with the structural and lithological setting, provides compelling evidence supporting Coyote as a high-priority target for drill testing."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Enters into Technology Data Acquisition Agreement

Stallion Uranium Enters into Technology Data Acquisition Agreement

 

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that, it has entered into a technology data acquisition agreement (the " Agreement ") dated April 24 th 2025, amongst the Company and Matthew J. Mason (the " Lessor ") to enhance exploration efforts across its expansive uranium land package in the Athabasca Basin, Saskatchewan. The Lessor holds the exclusive license to certain proprietary technology and know how that can be used to assist in area prioritization selection for the purposes of exploration for minerals (the " Technology " or " Haystack ").

 

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Athena Gold

Athena Gold Closes Private Placement

Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena Gold" or the "Company") is pleased to announce the closing of a non-brokered private placement previously announced on April 21, 2025 (the "Offering"). The Company has issued 3,322,000 units (the "Units") at a price of CAD $0.05 per Unit for gross proceeds of CAD $166,100.

Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of a common share purchase warrant (a "Warrant"). Each whole Warrant is exercisable into one Common Share at a price of CAD $0.12 per Warrant for a period of thirty-six months from the date of issuance, subject to the following acceleration provision. If, at any time after the date that is 4 months and one day after the date of issuance of the Warrants, the average volume weighted trading price of the Company's Common Shares on the Canadian Securities Exchange (or such other stock exchange on which the Common Shares may be traded from time to time) is at or above CAD $0.20 per share for a period of 10 consecutive trading days (the "Triggering Event"), the Company may at any time, after the Triggering Event, accelerate the expiry date of the Warrants by giving ten calendar days notice to the holders of the Warrants, by way of news release, and in such case the Warrants will expire on the first day that is 30 calendar days after the date on which such notice is given by the Company announcing the Triggering Event.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less

Latest Press Releases

Related News

×